Piper Jaffray Comments On Watson Pharmaceuticals

According to Piper Jaffray, Watson Pharmaceuticals WPI, PT and rating are reiterated. Piper Jaffray has reiterated a PT of $78 and a rating of Overweight. EPS estimates are currently set at $4.44 for FY11 and $6.09 for FY12, with estimates nearing $7 for FY13. Watson closed yesterday at $68.62.